# Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Source: https://onco.cc/trials/nct06145048/  
OnCo record `nct06145048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abenacianine run by Vergent Bioscience, Inc., completed.

## Summary

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. is a phase 2 interventional study registered as NCT06145048 by Vergent Bioscience, Inc., with 89 participants enrolled, started 2023-10-05. Conditions recorded: Lung Cancer and Lung Metastases. Interventions recorded: VGT-309.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06145048
- Phase: 2
- Setting: A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung
- Sponsor: Vergent Bioscience, Inc.
- Enrolled: 89

## Sources

- ClinicalTrials.gov NCT06145048: https://clinicaltrials.gov/study/NCT06145048

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- drugs: [Abenacianine](https://onco.cc/drugs/abenacianine/)
- companies: [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct06145048.json